Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$84.950.00%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put CRNX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementModerate volatility — typically moves about 0% a day.
View RiskMostly healthy — no soft spokes
CRNX’s case rests on rapid revenue expansion, though management has been unsteady and earnings remain unprofitable. Revenue grew 243% year over year in Q2 FY2026, and reported GAAP EPS beat consensus. The desk provides no valuation multiple or priced-in expectations, so whether the price reflects growth is unclear. Our model puts the next-quarter miss probability near 31%. A guidance cut is a specific downside scenario, though no such cut is reported. Our read remains intact; this read is provisional.
Trailing returns as of 2026-09-02. CRNX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering CRNX (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for CRNX in the last 4 months.
Continue this research
Compare CRNX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CRNX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CRNX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-02. EPS is implied from price ÷ P/E. Not investment advice.
Current $84.95
The last 12 months of price, then the range of analyst 12-month targets from today’s $84.95.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.